

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

Eastern Cooperative Oncology Group Performance Status Scale

RRID:SCR_026432

Type: Tool

Proper Citation

Eastern Cooperative Oncology Group Performance Status Scale (RRID:SCR_026432)

Resource Information

URL: <https://ecog-acrin.org/resources/ecog-performance-status/>

Proper Citation: Eastern Cooperative Oncology Group Performance Status Scale (RRID:SCR_026432)

Description: ECOG Performance Scale describes patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). Standard criteria for measuring how the disease impacts patient's daily living abilities. Used to assess the functional status of patient.

Synonyms: ECOG Performance Status Scale

Resource Type: organization portal, portal, standard specification, narrative resource, data or information resource

Keywords: ECOG-ACRIN Cancer Research Group, patient's performance status, assess patient functional status, conduct clinical trials,

Funding: NCI

Availability: Free, Freely available

Resource Name: Eastern Cooperative Oncology Group Performance Status Scale

Resource ID: SCR_026432

Record Creation Time: 20250219T060352+0000

Record Last Update: 20260804T043856+0000

Ratings and Alerts

No rating or validation information has been found for Eastern Cooperative Oncology Group Performance Status Scale.

No alerts have been found for Eastern Cooperative Oncology Group Performance Status Scale.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Freitas DMO, et al. (2025) Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study. Future science OA, 11(1), 2550917.

Dumas O, et al. (2025) The epiMelanoma test enables plasma-based detection of melanoma and prediction of immunotherapy response. Scientific reports, 15(1), 30710.

Ahmed J, et al. (2025) Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers. Journal for immunotherapy of cancer, 13(12).